1. Discovery of orally active, pyrrolidinone-based progesterone receptor partial agonists
- Author
-
Rakesh Nagilla, Sharada Manns, Eugene L. Stewart, Marlys Hammond, Tram H. Hoang, Scott K. Thompson, Walter Trizna, Chaya Duraiswami, Eugene T. Grygielko, Thuy B. Tran, James S. Frazee, Kevin P. Madauss, Johnson Latisha C, Shawn P. Williams, Lindsay E. Glace, David G. Washburn, and Jeffrey D. Bray
- Subjects
Agonist ,medicine.drug_class ,Stereochemistry ,Clinical Biochemistry ,hERG ,Administration, Oral ,Pharmaceutical Science ,Pharmacology ,Biochemistry ,Partial agonist ,Structure-Activity Relationship ,chemistry.chemical_compound ,In vivo ,Drug Discovery ,Progesterone receptor ,medicine ,Animals ,Humans ,Pyrrolidinones ,Molecular Biology ,Binding Sites ,biology ,Organic Chemistry ,Haplorhini ,Ether-A-Go-Go Potassium Channels ,Rats ,Nuclear receptor ,chemistry ,biology.protein ,Molecular Medicine ,Receptors, Progesterone ,Lead compound - Abstract
We have designed and synthesized a novel series of pyrrolidinones as progesterone receptor partial agonists. Compounds from this series had improved AR selectivity, rat pharmacokinetic properties, and in vivo potency compared to the lead compound. In addition, these compounds had improved selectivity against hERG channel inhibition.
- Published
- 2009
- Full Text
- View/download PDF